Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

10.6%

12 terminated/withdrawn out of 113 trials

Success Rate

81.0%

-5.6% vs industry average

Late-Stage Pipeline

7%

8 trials in Phase 3/4

Results Transparency

110%

56 of 51 completed trials have results

Key Signals

16 recruiting56 with results12 terminated

Enrollment Performance

Analytics

N/A
60(82.2%)
Phase 2
5(6.8%)
Phase 3
4(5.5%)
Phase 4
4(5.5%)
73Total
N/A(60)
Phase 2(5)
Phase 3(4)
Phase 4(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (113)

Showing 20 of 113 trials
NCT03821129Not ApplicableRecruiting

GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study

Role: lead

NCT07147569Recruiting

TAMBE Japan Post-Marketing Surveillance

Role: lead

NCT07564375Not ApplicableNot Yet Recruiting

MBA Early Feasibility Study

Role: lead

NCT07538609Not ApplicableNot Yet Recruiting

The GORE® VIABAHN® FORTEGRA Venous Stent Post-Approval Study

Role: lead

NCT05409976Not ApplicableActive Not Recruiting

The GORE® VIABAHN® FORTEGRA Venous Stent IVC Study

Role: lead

NCT05800743Not ApplicableEnrolling By Invitation

Evaluation of the GORE® Ascending Stent Graft

Role: lead

NCT03720704Active Not Recruiting

Post-Market Registry of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis Implanted in Peripheral Vessels

Role: lead

NCT06827990Not ApplicableRecruiting

GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections

Role: lead

NCT05489588Not ApplicableRecruiting

The GORE® VIABAHN® FORTEGRA Venous Stent Iliofemoral Study

Role: lead

NCT06872905Recruiting

Real-World Data Collection of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis When Used in Covered Endovascular Reconstruction of the Aortic Bifurcation (CERAB) to Treat Aortoiliac Occlusive Disease

Role: lead

NCT05387954Phase 3Recruiting

PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years

Role: collaborator

NCT07480395Not Yet Recruiting

Real-World Data Collection of the GORE Devices When Used in the Treatment of Aortic Pathologies Which Requires the Incorporation of the Visceral Arteries.

Role: lead

NCT02985684Not ApplicableCompleted

Safety and Efficacy Study of Transcatheter Closure of Ostium Secundum ASDs

Role: lead

NCT02777593Not ApplicableActive Not Recruiting

Evaluation of the GORE® TBE Device in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta, Zone 2

Role: lead

NCT07166133Not ApplicableNot Yet Recruiting

GORE® TAG® Thoracic Branch Endoprosthesis Zone 0/1 Post-Approval Study

Role: lead

NCT03728985Not ApplicableActive Not Recruiting

Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms

Role: lead

NCT05557058Not ApplicableActive Not Recruiting

GORE Glaucoma Drainage Implant Clinical Study Dominican Republic

Role: lead

NCT05442489Unknown

Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of the Thoracoabdominal and Pararenal Aortic Aneurysms (TAMBE)

Role: lead

NCT04718168Not ApplicableRecruiting

GORE® ENFORM Biomaterial Product Study

Role: lead

NCT06578741Not ApplicableEnrolling By Invitation

GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis Post-Approval Study

Role: lead